Abstract
Summary
The Europe PCR-based infectious diseases market is expected to reach USD 1,829,817.21 thousand by 2031 from USD 1,131,805.47 thousand in 2023, growing with a CAGR of 6.5% in the forecast period of 2024 to 2031.
Market Segmentation
Europe PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, and Rest of Europe) – Industry Trends and Forecast to 2031
Overview of Europe PCR-based Infectious Diseases Market Dynamics
Driver
• Increasing PCR-based research activities
Restraint
• High cost of PCR test services
Opportunity
• Disease surveillance for early detection and monitoring of infectious diseases
Market Players
Some of the major market players operating in the Europe PCR-based infectious diseases market are:
• DNA Labs India
• DrSafeHands
• Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
• Max Lab
• MicroGen Diagnostics
• pathlab
• The Washington Travel Clinic
• Clarewell Clinics
• AZOVA
• One Life Home Health Care Center
• LalPathLabs
Table of Contents
1 INTRODUCTION 44
1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF EUROPE PCR-BASED INFECTIOUS DISEASES MARKET 44
1.4 CURRENCY AND PRICING 45
1.5 LIMITATIONS 46
1.6 MARKETS COVERED 46
2 MARKET SEGMENTATION 49
2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 DBMR TRIPOD DATA VALIDATION MODEL 52
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.6 MULTIVARIATE MODELLING 56
2.7 MARKET APPLICATION COVERAGE GRID 57
2.8 TEST TYPE LIFELINE CURVE 58
2.9 DBMR MARKET POSITION GRID 59
2.10 VENDOR SHARE ANALYSIS 60
2.11 SECONDARY SOURCES 61
2.12 ASSUMPTIONS 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 65
4.1 PESTEL ANALYSIS 66
4.2 PORTER’S FIVE FORCES 67
5 MARKET OVERVIEW 68
5.1 DRIVERS 70
5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 70
5.1.2 RISING CASES OF INFECTIOUS DISEASES 70
5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 71
5.2 RESTRAINTS 72
5.2.1 HIGH COST OF PCR TEST SERVICES 72
5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 73
5.3 OPPORTUNITIES 74
5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 74
5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 74
5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 75
5.4 CHALLENGES 76
5.4.1 DATA SECURITY AND PRIVACY CONCERNS 76
5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 76
6 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 78
6.1 OVERVIEW 79
6.2 TUBERCULOSIS PCR TEST 85
6.3 HEPATITIS PCR TEST 85
6.3.1 HEPATITIS C PCR TEST 86
6.3.2 HEPATITIS B PCR TEST 86
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 87
6.5 INFLUENZA PCR TEST 87
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 88
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 88
6.8 GONORRHEA PCR TEST 89
6.9 SALMONELLOSIS PCR TEST 89
6.10 ROTAVIRUS PCR TEST 90
6.11 BORDETELLA PCR TEST 90
6.12 H. PYLORI PCR TEST 91
6.13 SARS (COVID-19) PCR TEST 91
6.14 NOROVIRUS PCR TEST 92
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 92
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 93
6.17 ENTEROCOCCUS PCR TEST 93
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 94
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 94
6.20 OTHERS PCR TEST 95
7 EUROPE PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 96
7.1 OVERVIEW 97
7.2 VIRAL INFECTION 100
7.2.1 SARS (COVID-19) INFECTION 100
7.2.2 ROTAVIRUS INFECTION 100
7.2.3 NOROVIRUS INFECTION 100
7.2.4 OTHERS 101
7.3 RESPIRATORY TRACT INFECTION 101
7.3.1 INFLUENZA 101
7.3.2 TUBERCULOSIS 101
7.3.3 BORDETELLA 102
7.4 SEXUALLY TRANSMITTED INFECTION 102
7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 103
7.4.2 GONORRHEA 103
7.4.3 HEAPTITIS 103
7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 103
7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 103
7.4.6 MYCOPLASMA GENITALIUM (MG) 103
7.4.7 OTHERS 103
7.5 HOSPITAL ACQUIRED INFECTIONS 104
7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 104
7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 104
7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 105
7.5.4 OTHERS 105
7.6 OTHER INFECTIONS 105
7.6.1 SALMONELLOSIS 105
7.6.2 H. PYLORI 106
7.6.3 ENTEROCOCCUS INFECTIONS 106
7.6.4 OTHERS 106
8 EUROPE PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 107
8.1 OVERVIEW 108
8.2 VIRAL 111
8.3 BACTERIAL 111
8.4 FUNGAL 112
8.5 PROTOZOA 112
8.6 OTHERS 113
9 EUROPE PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 114
9.1 OVERVIEW 115
9.2 RT PCR 118
9.3 MULTIPLEX PCR 118
9.4 OTHERS 119
10 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 120
10.1 OVERVIEW 121
10.2 GERIATRIC 124
10.3 PEDIATRIC 124
10.4 ADULTS 125
11 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 126
11.1 OVERVIEW 127
11.2 LABORATORY BASED TESTING 130
11.3 POINT OF CARE TESTING 130
12 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 131
12.1 OVERVIEW 132
12.2 DIAGNOSTIC CENTERS 135
12.3 HOSPITAL 135
12.4 CLINICS 136
12.5 COMMUNITY HEALTH CENTERS 136
12.6 ACADEMIC AND RESEARCH INSTITUTES 137
12.7 HOME HEALTHCARE 137
12.8 OTHERS 138
13 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 139
13.1 EUROPE 142
13.1.1 GERMANY 151
13.1.2 FRANCE 159
13.1.3 U.K 167
13.1.4 ITALY 175
13.1.5 RUSSIA 183
13.1.6 SPAIN 191
13.1.7 TURKEY 199
13.1.8 NETHERLANDS 207
13.1.9 SWITZERLAND 215
13.1.10 BELGIUM 223
13.1.11 HUNGARY 231
13.1.12 REST OF EUROPE 239
14 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 242
14.1 COMPANY SHARE ANALYSIS: EUROPE 242
15 SWOT ANALYSIS 243
16 COMPANY PROFILE 244
16.1 MICROGEN DIAGNOSTICS 244
16.1.1 COMPANY SNAPSHOT 244
16.1.2 SERVICE PORTFOLIO 244
16.1.3 RECENT DEVELOPMENTS 245
16.2 MAX LAB 246
16.2.1 COMPANY SNAPSHOT 246
16.2.2 SERVICE PORTFOLIO 246
16.3 DNA LABS INDIA 248
16.3.1 COMPANY SNAPSHOT 248
16.3.2 SERVICE PORTFOLIO 248
16.3.3 RECENT DEVELOPMENT 249
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD 250
16.4.1 COMPANY SNAPSHOT 250
16.4.2 SERVICE PORTFOLIO 250
16.4.3 RECENT DEVELOPMENT 251
16.5 LALPATHLABS 252
16.5.1 COMPANY SNAPSHOT 252
16.5.2 REVENUE ANALYSIS 252
16.5.3 PRODUCT PORTFOLIO 253
16.5.4 RECENT DEVELOPMENTS 253
16.6 AZOVA 254
16.6.1 COMPANY SNAPSHOT 254
16.6.2 PRODUCT PORTFOLIO 254
16.6.3 RECENT DEVELOPMENTS 254
16.7 CLAREWELL CLINICS 255
16.7.1 COMPANY SNAPSHOT 255
16.7.2 PRODUCT DESCRIPTION 255
16.7.3 RECENT DEVELOPMENTS 255
16.8 DRSAFEHANDS 256
16.8.1 COMPANY SNAPSHOT 256
16.8.2 SERVICE PORTFOLIO 256
16.8.3 RECENT DEVELOPMENT 256
16.9 ONE LIFE HOME HEALTH CARE CENTER 257
16.9.1 COMPANY SNAPSHOT 257
16.9.2 PRODUCT DESCRIPTION 257
16.9.3 RECENT DEVELOPMENTS 257
16.10 PATHLAB 258
16.10.1 COMPANY SNAPSHOT 258
16.10.2 SERVICE PORTFOLIO 258
16.10.3 RECENT DEVELOPMENT 258
16.11 THE WASHINGTON TRAVEL CLINIC 259
16.11.1 COMPANY SNAPSHOT 259
16.11.2 SERVICE PORTFOLIO 259
16.11.3 RECENT DEVELOPMENT 260
17 QUESTIONNAIRE 261
18 RELATED REPORTS 265